Poly Medicure Quarterly Results for Trading Insights
In Mar 2026, Poly Medicure (POLYMED) reported revenue ₹554 Cr and net profit ₹65 Cr — revenue +18.6% YoY. Also explore POLYMED share price history to track price trends across different timeframes.
POLYMED Quarterly Results — Revenue, Profit & EPS Highlights
Poly Medicure latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Poly Medicure screener.
- Revenue of ₹554 Cr in Mar 2026 (+15.7% vs Sept 2025, +18.6% vs Mar 2025)
- Net Profit of ₹65 Cr in Mar 2026 (-29.3% vs Sept 2025, -29.3% vs Mar 2025)
- EBITDA of ₹130 Cr in Mar 2026 (-13.3% vs Sept 2025)
- Operating Margin of 21.0% in Mar 2026 (-5.0pp vs Sept 2025)
- Earnings Per Share of ₹6.54 in Mar 2026 (-27.8% vs Sept 2025)
Poly Medicure Quarterly Results — Revenue, EBITDA, Net Profit & EPS
POLYMED quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 554 | 479 | 467 | 447 | 522 | 15.7% | 18.6% |
| Net Profit (₹ Cr) | 65 | 92 | 92 | 93 | 71 | - | - |
| EBITDA (₹ Cr) | 130 | 150 | 146 | 149 | 132 | - | - |
| EPS (₹) | 6.54 | 9.06 | 8.92 | 9.19 | 7.00 | - | - |
| Operating Margin (%) | 21.0% | 26.0% | 27.0% | 26.0% | 21.0% | - | - |
POLYMED Share Price Trend — 1-Year Movement Across Quarterly Results
Poly Medicure 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse Poly Medicure annual reports for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
POLYMED vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Poly Medicure latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹454,122.13 Cr | 1904.8 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 168.6 |
|
Divis Laboratories
Mar 2026 |
₹174,081.02 Cr | 6757.0 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 238.7 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹161,380.94 Cr | 4768.3 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.3 |
|
Cipla
Mar 2026 |
₹117,800.00 Cr | 1458.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 212.3 |
|
Dr Reddys Laborator…
Mar 2026 |
₹114,691.88 Cr | 1374.1 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 518.5 |
All amounts in ₹ Crores